Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2020 Dec 9;160(4):1151–1163.e3. doi: 10.1053/j.gastro.2020.11.045

Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study

Luca S Belli 1,, Constantino Fondevila 2, Paolo A Cortesi 3, Sara Conti 3, Vincent Karam 4, Rene Adam 4, Audrey Coilly 5, Bo Goran Ericzon 6, Carmelo Loinaz 7, Valentin Cuervas-Mons 8, Marco Zambelli 9, Laura Llado 10, Fernando Diaz-Fontenla 11, Federica Invernizzi 12, Damiano Patrono 13, Francois Faitot 14, Sherrie Bhooori 15, Jacques Pirenne 16, Giovanni Perricone 1, Giulia Magini 17, Lluis Castells 18, Oliver Detry 19, Pablo Mart Cruchaga 20, Jordi Colmenero 2, Frederick Berrevoet 21, Gonzalo Rodriguez 22, Dirk Ysebaert 23, Sylvie Radenne 24, Herold Metselaar 25, Cristina Morelli 26, Luciano G De Carlis 27, Wojciech G Polak 28, Christophe Duvoux 29; ELITA-ELTR COVID-19 Registry
PMCID: PMC7724463  PMID: 33307029

Abstract

Background and Aims

Despite concerns that liver transplant (LT) recipients may be at increased risk of unfavorable outcomes from COVID-19 due the high prevalence of co-morbidities, immunosuppression and ageing, a detailed analysis of their effects in large studies is lacking.

Methods

Data from adult LT recipients with laboratory confirmed SARS-CoV2 infection were collected across Europe. All consecutive patients with symptoms were included in the analysis.

Results

Between March 1 and June 27, 2020, data from 243 adult symptomatic cases from 36 centers and 9 countries were collected. Thirty-nine (16%) were managed as outpatients while 204 (84%) required hospitalization including admission to the ICU (39 of 204, 19.1%). Forty-nine (20.2%) patients died after a median of 13.5 (10–23) days, respiratory failure was the major cause. After multivariable Cox regression analysis, age >70 (HR, 4.16; 95% CI, 1.78–9.73) had a negative effect and tacrolimus (TAC) use (HR, 0.55; 95% CI, 0.31–0.99) had a positive independent effect on survival. The role of co-morbidities was strongly influenced by the dominant effect of age where comorbidities increased with the increasing age of the recipients. In a second model excluding age, both diabetes (HR, 1.95; 95% CI, 1.06–3.58) and chronic kidney disease (HR, 1.97; 95% CI, 1.05–3.67) emerged as associated with death

Conclusions

Twenty-five percent of patients requiring hospitalization for COVID-19 died, the risk being higher in patients older than 70 and with medical co-morbidities, such as impaired renal function and diabetes. Conversely, the use of TAC was associated with a better survival thus encouraging clinicians to keep TAC at the usual dose.

Keywords: COVID-19, Liver transplantation, Outcome, Tacrolimus

Abbreviations used in this paper: ALT, alanine aminotransferase; CI, confidence interval; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; CsA, cyclosporine A; ELITA, European Liver Transplantation Association; ELTR, European Liver Transplant Registry; ICU, intensive care unit; LT, liver transplant; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin; SARS-CoV2, severe acute respiratory syndrome coronavirus 2; TAC, tacrolimus

Graphical abstract

graphic file with name fx1_lrg.jpg


See editorial on page 1012.

What You Need to Know.

Background and Context

Few studies have analyzed the impact of Cocid-19 in liver transplant recipients and the association of co-morbidities, immunosuppression and ageing on the mortality risk.

New Findings

Age > 70 and tacrolimus use had respectively a negative and a positive independent effect on survival. The role of co-morbidities was strongly influenced by the dominant effect of age as the number of comorbidities increased with the increasing age of the recipients.

Limitations

Although we attempted to collect data on major co-variables there remains the possibility of missing confounders.

Impact

Thees findings should encourage clinicians to keep Tacrolimus at the usual dose as it may be beneficial when treating COVID-19.

The current coronavirus disease 2019 (COVID-19) pandemic has presented unforeseen challenges to health care systems worldwide, with several issues remaining unmet. To date, firm knowledge on disease evolution, risk factors, and optimal management in specific categories of patients is lacking. All transplant recipients are potentially vulnerable to severe acute respiratory syndrome coronavirus (CoV) 2 (SARS-CoV-2) infection, with immune suppression, aging, and metabolic or cardiovascular comorbidities likely being risk factors for symptomatic disease and its severe complications.1 Liver transplant (LT) patients, in particular, represent one of the largest immunosuppressed cohorts in Europe, with 102,116 alive recipients being reported in the European Liver Transplant Registry (ELTR), 42,432 (41.6%) of whom are in their 60s and 12,669 in their 70s or older.2

At present, available data related to COVID-19 in LT patients are limited to a small number of case series,3, 4, 5 to preliminary reports from 2 international registries,6, 7, 8 and to a single international prospective cohort of 57 patients.9 All authors agreed that greater case numbers were urgently required to accurately improve our understanding of individual risk in LT recipients. Thus, a large-scale collaborative study promoted by the European Liver Transplant Association (ELITA) and European Liver Transplant Registry (ELTR) was performed, the main aim being the search for risk factors associated with mortality during the COVID-19 pandemic and with a specific focus on comorbidities and immunosuppression.

Methods

Study Population

ELITA called for a COVID-19 study, which was circulated on March 30, 2020, among 149 LT centers affiliated to ELTR and located in 30 European countries. All centers that reported at least 1 case were provided with a database and instructions on how to record structured data. Data collection was managed by ELTR. Responses were received from 114 centers (76.5%), with 56 centers (38%) having observed COVID-19 in adult LT recipients between March 1 and May 19, 2020. The study included all patients with symptoms and with SARS-CoV-2 infection confirmed by a positive result on a reverse-transcriptase polymerase chain reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab or on bronchoalveolar lavage.

Data Collection and Definitions

Demographic and clinical data, including clinical symptoms or signs at presentation, laboratory, and radiologic results during COVID-19 management, as well as administered antiviral therapies and antithrombotic prophylaxis were retrospectively collected. All laboratory tests and radiologic assessments were performed at the discretion of the treating physician. Serum creatinine was converted to mg/dL for analysis. Information on baseline immunosuppression and on changes during COVID-19, namely reduction or discontinuation, was also obtained.

Obesity was defined as a given body mass index of >30 kg/m2. Liver injury during COVID-19 was defined as alanine aminotransferase (ALT) level >30 IU/L for male patients and 19 IU/L for female patients in those with normal ALT levels at the last outpatient visit.10 Hepatic flare was defined as ALT level ≥5 times the upper limit of normal. The time on study started at occurrence of COVID-19 symptoms.

All submitted files from each center were manually reviewed to assess for data quality, completeness, and inconsistencies. In addition, submitting clinicians were contacted and asked to provide corrections or data integration whenever needed.

Ethical and Regulatory Approval

Data were collected in accordance with General Data Protection Regulation, the European Union legislation, and the ELTR privacy policy.

Statistical Analysis

Analysis was led by the Research Centre on Public Health, University of Milan-Bicocca, Monza, Italy. A descriptive analysis of the cohort was performed on the overall population and after stratifying the population by site of management: at home, in general wards, or in intensive care units (ICUs). Categorical variables are summarized through percentages, and continuous variables through median, first quartile and third quartile. Categorical variables were compared using the χ2 or Fisher’s exact tests; continuous variables were compared using the Mann-Whitney U test or the Kruskal-Wallis test, when appropriate. All tests were 2-sided and used a significance level of 0.05.

The rates of missing data for each variable were reported. For each patient, the time between the date of COVID-19 symptoms and death or end of follow-up was computed, and the association between mortality and baseline patients’ characteristics was evaluated through univariate Cox’s proportional hazard models. All characteristic analyzed in the univariate model were included in a stepwise selection process that identified the best multivariate model. The same process was repeated after excluding age from potential predictors. Given the exploratory nature of the study and the limited sample size, a 0.1 significance level was established to retain predictors in the final multivariate models possibly favoring the tracing of borderline significant associations that could be the basis for further studies on wider samples. All statistical analyses were conducted using SAS 9.4 software (SAS Institute, Inc, Cary, NC) and R 4.0.0 software (R Core Team, Vienna, Austria). The map was drawn using QGIS 3.10 software (QGIS Development Team).

Results

Demographic and General Characteristics of Patients

The COVID-19 pandemic was not uniformly experienced in Europe, with large areas being spared. This explains why of the 111 centers responding to the ELITA/ELTR call, only 36 centers from 9 European countries observed at least 1 patient with RT-PCR–confirmed SARS-CoV-2 infection (Figures 1 and 2 ). Of the 29,981 alive patients in regular follow-up at the participating centers, 258 (0.9%) have been consecutively reported in the registry. Excluded from the study were 11 patients (4.3%) who were asymptomatic, in whom the RT-PCR test was performed according to surveillance protocols in case of contact with a SARS-CoV-2–positive individual. Four additional patients were excluded because they were aged <18 years. The remaining 243 symptomatic patients were considered for statistical analysis, with 39 patients (16%) receiving home care, and the remaining 204 requiring hospitalization (Figure 2). Of these, 167 patients (68.7%) were treated in a general ward and 37 in ICUs. Baseline patient characteristics are reported in Table 1 . Thirty-two LT recipients with COVID-10 analyzed in this study were also included in the report from Becchetti et al.9

Figure 1.

Figure 1

Flowchart shows the selection of the study population.

Figure 2.

Figure 2

Patients with COVID-19 included in the study by country.

Table 1.

Baseline Characteristics of the Study Population

Variables Place of management
Total (N = 243) P value
Home (n = 39) Ward (n = 167) ICU (n = 37)
Male sex 24 (61.54) 121 (72.46) 26 (70.27) 171 (70.37) .4051
Age at symptoms, ya,b 54 (37.0–61.0) 64 (57.0–72.0) 64 (58.0–68.0) 63 (55.0–69.0) <.0001
Age class at symptoms, ya,b <.0001
 ≤50 16 (41.03) 20 (11.98) 3 (8.11) 39 (16.05)
 50–60 11 (28.21) 39 (23.35) 10 (27.03) 60 (24.69)
 60–70 9 (23.08) 59 (35.33) 20 (54.05) 88 (36.21)
 >70 1 (2.56) 48 (28.74) 4 (10.81) 53 (21.81)
Location of patient at occurrence of symptomsb .0119
 Home 39 (100.00) 148 (88.62) 30 (81.08) 217 (89.30)
 Hospital 0 (0.00) 19 (11.38) 7 (18.92) 26 (10.70)
Time between last LT and COVID-19 symptoms, y 6 (2.2–10.9) 9 (3.8–15.4) 5 (1.5–13.3) 8 (3.1–15.0) .0295
Time between last LT and COVID-19 symptoms .1005
 <1 year 5 (12.82) 19 (11.38) 7 (18.92) 31 (12.76)
 1–5 years 12 (30.77) 32 (19.16) 11 (29.73) 55 (22.63)
 5–10 years 9 (23.08) 34 (20.36) 7 (18.92) 50 (20.58)
 ≥10 years 10 (25.64) 81 (48.50) 10 (27.03) 101 (41.56)
 Missing 3 (7.69) 1 (0.60) 2 (5.41) 6 (2.47)
Indication for LT
 Decompensated cirrhosis 21 (53.85) 96 (57.49) 24 (64.86) 141 (58.02) .6034
 Hepatocellular carcinoma 8 (20.51) 43 (25.75) 12 (32.43) 63 (25.93) .4933
 Otherb 10 (25.64) 29 (17.37) 1 (2.70) 40 (16.46) .0226
Etiology
 Alcohola 3 (7.69) 49 (29.34) 8 (21.62) 60 (24.69) .0149
 After nonalcoholic steatohepatitis 2 (5.13) 10 (5.99) 6 (16.22) 18 (7.41) .1262
 Hepatitis B virus 5 (12.82) 34 (20.36) 4 (10.81) 43 (17.70) .2492
 Hepatitis C virus active or inactive 10 (25.64) 41 (24.55) 11 (29.73) 62 (25.51) .8282
 Othera 20 (51.28) 49 (29.34) 10 (27.03) 79 (32.51) .0256
 Missing 0 (0.00) 2 (1.20) 0 (0.00) 2 (0.82)
Body mass index, kg/m2 25.5 (22.0–28.9) 25.8 (23.4–29.4) 27.9 (24.5–29.9) 25.9 (23.4–29.4) .1701
 Missing 3 (7.69) 18 (10.78) 1 (2.70) 22 (9.05)
 Body mass index >30 kg/m2 7 (17.95) 30 (17.96) 9 (24.32) 46 (18.93) .7924
Comorbidities
 Nonea,b 19 (48.72) 35 (20.96) 3 (8.11) 57 (23.46) <.0001
 Diabetesb 8 (20.51) 67 (40.12) 19 (51.35) 94 (38.68) .0176
 Hypertensionb,c 11 (28.21) 71 (42.51) 29 (78.38) 111 (45.68) <.0001
 Chronic lung disease 3 (7.69) 20 (11.98) 2 (5.41) 25 (10.29) .5267
 Chronic kidney diseased 4 (10.26) 37 (22.16) 8 (21.62) 49 (20.16) .2419
 Coronary artery disease 3 (7.69) 9 (5.39) 5 (13.51) 17 (7.00) .2071
 Other 4 (10.26) 34 (20.36) 5 (13.51) 43 (17.70) .2541
Number of comorbiditiesa,b .0002
 0 19 (48.72) 35 (20.96) 3 (8.11) 57 (23.46)
 1 11 (28.21) 57 (34.13) 11 (29.73) 79 (32.51)
 ≥2 9 (23.08) 75 (44.91) 23 (62.16) 107 (44.03)
Drugs
 β-Blockers 6 (15.38) 34 (20.36) 10 (27.03) 50 (20.58) .4515
 ACE inhibitors or angiotensin II receptor antagonistsa,b 1 (2.56) 47 (28.14) 11 (29.73) 59 (24.28) .0025
Smoking .3508
 Missing 0 (0.00) 1 (0.60) 1 (2.70) 2 (0.82)
 No 35 (89.74) 151 (90.42) 30 (81.08) 216 (88.89)
 Yes 4 (10.26) 15 (8.98) 6 (16.22) 25 (10.29)
Type of immunosuppressante
 TAC 32 (82.05) 106 (63.47) 24 (64.86) 162 (66.67) .0831
 MMF 15 (38.46) 80 (47.90) 24 (64.86) 119 (48.97) .0627
 Steroids 7 (17.95) 35 (20.96) 14 (37.84) 56 (23.05) .0625
 mTOR 5 (12.82) 27 (16.17) 5 (13.51) 37 (15.23) .8296
 CsA 1 (2.56) 23 (13.77) 5 (13.51) 29 (11.93) .1188
 Other 0 (0.00) 1 (0.60) 0 (0.00) 1 (0.41) >.9999
Combinations of immunosuppressant
 CsA only 1 (2.56) 10 (5.99) 2 (5.41) 13 (5.35) .8264
 CsA, MMF 0 (0.00) 7 (4.19) 2 (5.41) 9 (3.70) .3842
 CsA, steroids 0 (0.00) 3 (1.80) 0 (0.00) 3 (1.23) .9999
 CsA, MMF, steroids 0 (0.00) 3 (1.80) 1 (2.70) 4 (1.65) .5697
 TAC only 12 (30.77) 36 (21.56) 6 (16.22) 54 (22.22) .2918
 TAC, MMF 12 (30.77) 35 (20.96) 5 (13.51) 52 (21.40) .1806
 TAC, mTOR 2 (5.13) 10 (5.99) 0 (0.00) 12 (4.94) .4209
 TAC, steroids, or other 6 (15.38) 16 (9.58) 5 (13.51) 27 (11.11) .4473
 TAC, MMF, mTOR 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
 TAC, MMF, steroidsb 0 (0.00) 9 (5.39) 6 (16.22) 15 (6.17) .011
 TAC, MMF, mTOR, steroids 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
 MMF only 3 (7.69) 17 (10.18) 4 (10.81) 24 (9.88) .8966
 MMF, mTOR 0 (0.00) 7 (4.19) 3 (8.11) 10 (4.12) .1712
 MMF, steroids 0 (0.00) 2 (1.20) 1 (2.70) 3 (1.23) .4484
 mTOR only 2 (5.13) 9 (5.39) 0 (0.00) 11 (4.53) .4577
 mTOR, steroids 1 (2.56) 1 (0.60) 0 (0.00) 2 (0.82) .5286
 Steroids only 0 (0.00) 2 (1.20) 0 (0.00) 2 (0.82) >.9999
Most recent values before symptoms
 White blood cells, 109/L 5.1 (4.4–6.5) 5.2 (3.9–6.7) 6.0 (4.3–6.7) 5.2 (4.0–6.7) .9274
 Bilirubin, mg/dL 0.8 (0.5–1.0) 0.6 (0.4–1.0) 0.6 (0.5–1.0) 0.7 (0.5–1.0) .7569
 Creatinine, mg/dLa,b 1.0 (0.9–1.1) 1.1 (0.9–1.5) 1.2 (1.0–1.6) 1.1 (0.9–1.4) .019
 ALT, U/L 23.0 (17.0–32.0) 20.0 (15.0–31.0) 23.0 (17.0–34.0) 20.0 (16.0–32.0) .3607

NOTE. Data are presented n (%) or median (1st–3rd quartile).

ACE, angiotensin converting enzyme; mTOR, mammalian target of rapamycin inhibitors.

a

P value ward vs home ≤.05.

b

P value ICU vs home ≤.05.

c

P value ICU vs ward ≤.05.

d

Plasma creatinine >2 mg/dL.

e

Patients can be treated with >1 therapy; therefore, percentages do not sum to 100.

Comorbidities

A total of 111 patients (45.7%) had arterial hypertension, 94 (38.7%) had diabetes mellitus, 49 (20.2%) had chronic kidney disease with a creatinine >2 mg/dL, and 25 (10.3%) had chronic lung diseases. Concurrent comorbidities were frequent, with 107 patients (44%) having ≥2 (Table 1). The prevalence of at least 2 comorbidities increased with age being observed in 25.3%, 53.4%, and 64.2% in recipients aged <60 years, 60 to 70 years, or >70 years, respectively.

Immunosuppressive Drugs and Other Drugs

Tacrolimus (TAC) and cyclosporine A (CsA) were considered as the main immunosuppressive drugs. Because some of the patients were off a calcineurin inhibitor (CNI), the proportion of patients receiving each immunosuppressive drug or combination of drugs was also obtained. At the time of analysis, 162 patients (66.7%) were on TAC, alone or in combination, 29 (11.9%) were on CsA alone or in combination, 119 (49.0%) were on mycophenolate mofetil (MMF) alone or in combination, and 37 (15.2%) were on mammalian target of rapamycin inhibitors alone or in combination (Table 1).

Clinical Presentation and Course of Liver Transplant Recipients With COVID-19

At the time of diagnosis, the most commonly self-reported symptoms included fever in 190 patients (78.2%), cough in 143 (58.8%), dyspnea in 82 (33.7%), muscle pain or asthenia in 90 (37.0%), anosmia or dysgeusia in 21 (8.6%), and diarrhea in 55 (22.6%). Radiologic findings on computed tomography scan or on chest radiography showed typical ground-glass opacities in 145 patients (59.7%) (Table 2 ). Overall, 137 patients (56.4%) required respiratory support during hospitalization, with 26 requiring noninvasive ventilation and 25 mechanical ventilation (Table 2). Specific anti–SARS-CoV-2 treatment was administered to 149 patients: 116 (47.7%) were treated with hydroxychloroquine alone or in combination, 41 (16.9%) with lopinavir-ritonavir, 34 (14.0%) with high doses of corticosteroids, and 15 (6.2%) with tocilizumab.

Table 2.

Clinical Presentation and Course After COVID-19 Symptoms

Variable Place of management
Total (N = 243) P value
Home (n = 39) Ward (n = 167) ICU (n = 37)
Symptoms: at clinical diagnosis
 Fever >37.2°Ca 25 (64.10) 137 (82.04) 28 (75.68) 190 (78.19) .0468
 Cough 21 (53.85) 106 (63.47) 16 (43.24) 143 (58.85) .0609
 Polypnea or dyspneaa,b,c 4 (10.26) 57 (34.13) 21 (56.76) 82 (33.74) .0001
 Diarrheaa 3 (7.69) 46 (27.54) 6 (16.22) 55 (22.63) .0171
 Anosmia and dysgeusiaa 9 (23.08) 10 (5.99) 2 (5.41) 21 (8.64) .0061
 Muscle paina 13 (33.33) 24 (14.37) 4 (10.81) 41 (16.87) .0098
 Confusion 0 (0.00) 4 (2.40) 3 (8.11) 7 (2.88) .0969
 Thoracic pain 3 (7.69) 11 (6.59) 1 (2.70) 15 (6.17) .717
 Asthenia 11 (28.21) 34 (20.36) 4 (10.81) 49 (20.16) .1669
 Other 4 (10.26) 11 (6.59) 0 (0.00) 15 (6.17) .1591
Time between symptoms and positive test, db 9 (3–19) 5 (2–9) 3 (0–7) 4 (2–10) .0226
Chest x-ray or thorax CT scan
 Noa,b 16 (41.03) 8 (4.79) 4 (10.81) 28 (11.52) <.0001
 Yes, normalb,c 15 (38.46) 51 (30.54) 0 (0.00) 66 (27.16) .0002
 Yes, ground-glass opacitiesa,b,c 7 (17.95) 106 (63.47) 32 (86.49) 145 (59.67) <.0001
 Yes, lobar opacitiesc 1 (2.56) 6 (3.59) 7 (18.92) 14 (5.76) .0044
 Ground-glass or lobar opacitiesa,b,c 8 (20.51) 108 (64.67) 33 (89.19) 149 (61.32) <.0001
Respiratory supportc <.0001
 Oxygen support 1 (50.00) 78 (79.59) 7 (18.92) 86 (62.77)
 Noninvasive ventilation 1 (50.00) 17 (17.35) 8 (21.62) 26 (18.98)
 Mechanical ventilation 0 (0.00) 3 (3.06) 22 (59.46) 25 (18.25)
Added lung infection
 Noneb,c 39 (100.00) 154 (92.22) 25 (67.57) 218 (89.71) <.0001
 Bacterialb 0 (0.00) 11 (6.59) 7 (18.92) 18 (7.41) .0064
 Fungalc 0 (0.00) 1 (0.60) 5 (13.51) 6 (2.47) .0011
 Other 0 (0.00) 2 (1.20) 0 (0.00) 2 (0.82) >.9999
Renal replacement therapyb,c 0 (0.00) 10 (5.99) 11 (29.73) 21 (8.64) <.0001
Vasoactive drugs (NA)b,c 1 (2.56) 1 (0.60) 19 (51.35) 21 (8.64) <.0001
Myocarditis 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
Peak laboratory values
 Bilirubin, mg/dLc 0.8 (0.5–1.1) 0.7 (0.4–1.0) 1.2 (0.8–2.7) 0.8 (0.5–1.2) .0034
 International normalized ratiob,c 1.1 (1.0–1.2) 1.1 (1.1–1.3) 1.3 (1.1–1.7) 1.1 (1.1–1.3) .0039
 Creatinine, mg/dLb,c 1.0 (0.9–1.6) 1.2 (0.9–1.8) 2.2 (1.2–4.0) 1.3 (0.9–2.0) .0009
 ALT, U/Lb,c 28.0 (19.0–39.0) 32.0 (19.0–51.5) 59.5 (32.5–134.5) 34.0 (20.0–55.0) .0014
COVID-19 therapy
 Noneab 33 (84.62) 46 (27.54) 15 (40.54) 94 (38.68) <.0001
 Lopinavir/ritonavira,b 0 (0.00) 35 (20.96) 6 (16.22) 41 (16.87) .007
 Hydroxychloroquinea,b,c 4 (10.26) 99 (59.28) 13 (35.14) 116 (47.74) <.0001
 High-dose steroidsa,b 0 (0.00) 26 (15.57) 8 (21.62) 34 (13.99) .0144
 Remdesevir 0 (0.00) 0 (0.00) 1 (2.70) 1 (0.41) .1523
 Tocilizumab 0 (0.00) 11 (6.59) 4 (10.81) 15 (6.17) .0962
 Azythromicina 2 (5.13) 57 (34.13) 8 (21.62) 67 (27.57) .0009
 Otherb 1 (2.56) 15 (8.98) 8 (21.62) 24 (9.88) .0215
Immunosuppression changes
 Yesab 4 (10.26) 71 (42.51) 22 (59.46) 97 (39.92) <.0001
 Stop CNI 0 (0.00) 11 (6.59) 5 (13.51) 16 (6.58) .0441
 25%-50% reduction in CNI 2 (5.13) 28 (16.77) 8 (21.62) 38 (15.64) .1091
 Stop antimetabolitesb 1 (2.56) 26 (15.57) 8 (21.62) 35 (14.40) .0455
 Stop mTOR inhibitors 0 (0.00) 9 (5.39) 1 (2.70) 10 (4.12) .3305
 Other 1 (2.56) 5 (2.99) 0 (0.00) 6 (2.47) .1479
Outcomea,b,c <.0001
 Alive 39 (100.00) 138 (82.63) 17 (45.95) 194 (79.84)
 Dead 0 (0.00) 29 (17.37) 20 (54.05) 49 (20.16)
Time between symptoms and last follow-up, db,c 70 (48–88) 66 (42–88) 29 (17–75) 65 (35–87) .007
 Missing 3 (7.69) 1 (0.60) 2 (5.41) 6 (2.47)
Cause of death
 Refractory pneumonia 23 (79.31) 15 (75.00) 38 (77.55) .7405
 Liver-related death
 Without lung failure 1 (3.45) 0 (0.00) 1 (2.04) >.9999
 With lung failure 2 (6.90) 1 (5.00) 3 (6.12) >.9999
 Other 3 (10.34) 4 (20.00) 7 (14.29) .4221
Heparina,b <.0001
 Missing 13 (33.33) 20 (11.98) 6 (16.22) 39 (16.05)
 No 24 (61.54) 53 (31.74) 10 (27.03) 87 (35.80)
 Yes 2 (5.13) 94 (56.29) 21 (56.76) 117 (48.15)
Average CNI level pre–COVID-19 .0235
 No CNI 4 (10.26) 5 (2.99) 1 (2.70) 10 (4.12)
 CsA ≤50 ng/L 1 (2.56) 6 (3.59) 4 (10.81) 11 (4.53)
 CsA 50–100 ng/L 1 (2.56) 2 (1.20) 0 (0.00) 3 (1.23)
 CsA >100 ng/L 0 (0.00) 35 (20.96) 6 (16.22) 41 (16.87)
 TAC ≤4 ng/mL 3 (7.69) 22 (13.17) 6 (16.22) 31 (12.76)
 TAC 4–6 ng/mL 10 (25.64) 25 (14.97) 6 (16.22) 41 (16.87)
 TAC >6 ng/mL 6 (15.38) 25 (14.97) 6 (16.22) 37 (15.23)

NOTE. Data are presented n (%) or median (1st–3rd quartile).

CT, computed tomography; mTOR, mammalian target of rapamycin; NA, noradrenaline.

a

P value ward vs home ≤.05

b

P value ICU vs home ≤.05

c

P value ICU vs ward ≤.05

Thromboprophylaxis, mainly with low-molecular-weight heparin, was started on COVID-19 diagnosis in 117 patients (48.2%). Thrombotic events occurred in 7 of 204 (3.4%) hospitalized patients, comprising 3 pulmonary embolisms, 2 deep vein thromboses, and 2 strokes.

An acute liver injury was observed in 56 patients with previous persistently normal ALT levels, being in the flare range in 10 patients. Acute rejection was reported in 3 patients. Notably, CNI had been withdrawn in 2 patients, and the dose of mammalian target of rapamycin had been halved in the third patient.

Forty-nine patients (20.2%) died after a median of 13.5 days (first–third quartile, 10–23 days) from the diagnosis of COVID-19. Causes of death were respiratory failure in 39 patients (77.6%), end-stage liver disease with respiratory failure in 2, end-stage liver disease without respiratory failure in 1, hemorrhagic shock in 2, pulmonary embolism in 1, metastatic cancer in 1 septic shock in 1, and septic complication from tracheal fistula in 1. Overall Kaplan-Meier survival from the date of COVID-19 symptoms is given in Figure 3 . Estimated a probability of survival was 88.2% (95% confidence interval [CI], 82.5%–92.1%) at 30 days and 84.4% (95% CI, 77.7%–89.2%) at 90 days.

Figure 3.

Figure 3

Kaplan-Meier survival curve from the date of COVID-19 symptoms (A) overall and (B) stratified by place of management.

Clinical Features and Outcomes of Liver Transplant Recipients With COVID-19 Treated at Home, in General Wards, and in Intensive Care Units

Baseline characteristics of patients with less severe symptoms who could be treated at home and those with more severe symptoms requiring hospitalization in general wards and ICUs are reported in Table 2. Patients treated at home were younger, had fewer comorbidities, and were more frequently receiving TAC as the primary immunosuppressant. Kaplan-Meier survival after stratification by place of management, at home, general ward, or ICU is provided in Figure 3. Patients managed at home survived, whereas the probability of survival at 30 days was 93.1% (95% CI, 86.7%–96.5%) and 57.0% (95% CI, 37.6%–72.4%), respectively, for patients in ward and in ICUs, and it declined to 89.8% (95% CI, 82.1%–94.3%) and 46.6% (95% CI, 26.2%–64.6%) at 90 days. Notably, 12 patients with advanced COVID-19 disease were not admitted to an ICU, 8 because they were deemed too sick for the ICU due to a combination of advanced age and severe comorbidities and 4 because ICUs were overwhelmed.

Factors Associated With Death

Factors by univariable analysis significantly associated with death were increased age of the recipient, time from LT, diabetes, chronic kidney disease, number of comorbidities, and use of TAC (Table 3 ). After multivariable analysis, advanced age (>70 vs <60 years) remained independently associated with an increased mortality risk (hazard ratio, 4.16; 95% CI, 1.78–9.73), whereas use of TAC was confirmed independently associated with a reduced mortality risk (hazard ratio, 0.55; 95% CI, 0.31–0.99). The Kaplan-Meier survival curves stratified by age (>70 or <70) and type of immunosuppressant (TAC vs non-TAC) may be helpful for the clinician to better understand the individual risk (Supplementary Figure 1).

Table 3.

Results From Univariate and Multivariate Analysis of Predictors of Mortality, From Cox’s Proportional Hazard Regression Models

Variable Univariate models
Multivariate models
HR (95% CI) P value HR (95% CI) P value
Age
 Linear (1-year increase) 1.06 (1.03–1.10) <.0001
 60–70 vs ≤60 years 2.58 (1.12–5.94) .0255 2.20 (0.94–5.13) .068
 >70 vs ≤60 years 5.49 (2.42–12.48) <.0001 4.16 (1.78–9.73) .001
Sex (male vs female) 1.39 (0.71–2.73) .3438
Indication for LT
 Decompensated cirrhosis 1.11 (0.61–2.00) .736
 Hepatocellular carcinoma 1.25 (0.67–2.34) .4846
 Other 0.63 (0.25–1.61) .3362
Time between LT and COVID-19 symptoms (1-year increase) 1.05 (1.01–1.09) .0054
Body mass index (1-unit increase) 1.00 (0.94–1.07) .9936
Comorbidities
 Diabetes 1.98 (1.11–3.54) .0212
 Hypertension 1.76 (0.98–3.17) .0584
 Chronic lung disease 0.55 (0.17–1.76) .3126
 Chronic kidney diseasea 2.20 (1.19–4.08) .0123 1.72 (0.92–3.22) .0912
 Coronary artery disease 1.37 (0.49–3.81) .5518
 Other 1.71 (0.89–3.31) .1095
Comorbidities, n
 1 vs 0 3.54 (1.02–12.33) .0468
 ≥2 vs 0 5.63 (1.72–18.50) .0044
Smoking (yes vs no) 1.62 (0.72–3.63) .241
Type of immunosuppressant
 CsA vs all other 2.29 (1.13–4.60) .0209
 TAC vs all other 0.43 (0.24–0.77) .0042 0.55 (0.31–0.99) .0472
 MMF vs all other 1.30 (0.73–2.33) .3704
 mTOR inhibitors vs all other 1.37 (0.66–2.84) .3969
Treatment with ACE inhibitors or angiotensin II receptor antagonists (yes vs no) 1.92 (1.06–3.49) .0328
Country
 Spain vs Other 1.52 (0.67–3.48) .3178
 Italy vs Other 1.34 (0.54–3.34) .5253
 France vs Other 1.48 (0.55–3.94) .4355
Center recruiting more than 9 patients vs other centers 1.47 (0.82–2.65) .1993

NOTE. Bold values are statistically significant (P < .05).

ACE, angiotensin converting enzyme; CT, computed tomography; HR, hazard ratio; mTOR, mammalian target of rapamycin.

a

Plasma creatinine >2 mg/dL.

Supplementary Figure 1.

Supplementary Figure 1

Kaplan-Meier curves for survival from the date of COVID-19 diagnosis, stratified by age (2 categories) and main immunosuppressant. Cya, cyclosporin A; FK, tacrolimus; mTOR, mammalian target of rapamycin.

Because the number of comorbidities increased with the increasing age of the recipient, a second model excluding age was constructed. This allowed diabetes and chronic renal failure to emerge as predictors of mortality, their effect having been shadowed in the first model by the dominant effect of age (Supplementary Table 1).

The interplay among age of the recipient, primary immunosuppressant, and chronic renal failure is summarized in Supplementary Table 2 and Supplementary Figure 2, where the negative impact of chronic kidney disease is dramatically evident in recipients not maintained on TAC. Finally, in Supplementary Table 3, patients receiving TAC-based vs non–TAC-based regimens are compared with respect to some relevant clinical variables such as age, time from transplant, chronic renal failure, concurrent exposure to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and presence of hepatocellular carcinoma. In fact, patients receiving TAC were younger and had fewer comorbidities, these variables being potentially associated with a better outcome. Conversely patients on TAC were much less frequently treated with angiotensin-converting enzyme or angiotensin receptor blocker inhibitors, this therapy being associated with a better outcome. All these variables were included in the multivariable analysis that confirmed the independent protective role of TAC.

Supplementary Figure 2.

Supplementary Figure 2

Kaplan-Meyer curves for survival from the date of COVID-19 diagnosis show the interplay between age of the recipient, primary immunosuppressant, and chronic renal failure (CRF). mTOR, mammalian target of rapamycin.

Discussion

As more than 200 countries worldwide are still struggling with the COVID-19 pandemic, all solid-organ transplant recipients are at risk of infection and poor outcome due to chronic immunosuppression, high rates of comorbidities, advanced age, and frequent hospitalization. We have analyzed the characteristics, management, and outcome of a large multinational European cohort of LT recipients with symptomatic SARS-CoV-2 infection.

Rates of hospitalization and death in the current study were 85% and 20.2%, confirming what we already showed in our preliminary report on the first 103 patients,7 where some patients were still experiencing their disease course. These findings concur with the 23% mortality risk reported by Webb et al,6 but compare unfavorably with the 12% mortality risk observed by Becchetti et al,9 possibly due to the lower percentage of patients requiring hospitalization in this latter study. Our study confirmed that abdominal symptoms and, more specifically, diarrhea are at least twice more frequent than in the general population9 and are possibly associated to MMF. This hypothesis is supported by the fact that almost 50% of the 26 patients maintained on MMF as the primary immunosuppressant had diarrhea as presenting symptom. Clinicians should therefore be vigilant and consider SARS-CoV-2 testing in transplant recipients presenting with diarrhea, particularly if using MMF.

However, the main finding of the present study is the significant variation in mortality risk with both age of the recipients and use of TAC as immunosuppressant. The role of advanced age confirms what has been extensively observed in the general population, with patients older than 70 having an increased 4-fold mortality risk.11, 12, 13, 14 The lower risk of death for patients maintained on TAC was unexpected and to our knowledge has not been previously reported. In particular Becchetti et al9 could not explore this association in their prospective cohort of 57 LT recipients with COVID-19 because the great majority of their patients were receiving TAC. Notably, in our analysis, the beneficial impact of TAC was robust and persisted after controlling for various confounders. The biological explanation of the potential favorable role of TAC is unknown but may be dual: inhibition of viral replication and interaction with the immune response. Some studies have shown that CoV replication, depends on active immunophilin pathways and that TAC is capable of strongly inhibiting the growth of some human CoV, notably SARS CoV-1, probably by binding the immunophilin FK506-binding proteins, although not specifically SARS-CoV-2.10 , 15 , 16

Another potential driver of the TAC protective effect could be related to the immunosuppressive property of this CNI.17 By inhibiting calcineurin and suppressing the early phase of T-cell activation, TAC reduces the production of many cytokines, notably proinflammatory cytokines, as tumor necrosis factor-α and interferon-γ, and possibly mitigates the cytokine storm that characterizes stage III COVID-19. Interestingly, this background recently prompted a group of Spanish investigators to test the effect of TAC in combination with steroids in the management of COVID-19 occurring in immunocompetent individuals (clinicaltrials.gov/ct2/show/NCT04341038). While waiting for studies on larger cohorts of transplant recipients that would allow a more precise estimate of the protective effect of TAC, reducing or withdrawing the doses of TAC during COVID-19 should be discouraged, if not indicated for other clinical reasons.

The role of comorbidities as relevant risk factors for mortality has been clearly demonstrated in the general population with COVID-19.18 Despite being highly prevalent among LT recipients,19 neither a specific comorbidity nor a combination of comorbidities emerged as independently associated with outcome. This is at least partly explained by the dominant effect of age as comorbidities increased with the increasing age of the recipients. Nevertheless, in our exploratory analysis, chronic renal failure, defined by a serum creatinine >2 mg/dL, maintained a trend of significance (P < .1) even if shadowed by the dominant effect of increasing age. Notably, the negative impact of renal failure on survival was particularly relevant in patients who were not receiving TAC, once again pointing to its possible protective role against COVID-19, at least in LT recipients.

Finally, therapy for COVID-19 differed across centers and countries and varied over time with the increasing knowledge in treating this new disease. Because large prospective randomized trials have recently demonstrated that corticosteroids and remdesivir are effective in severe cases, whereas hydroxychloroquine and lopinavir-ritonavir are not, new patients should be treated accordingly.20 , 21

This study has some strengths. It is, at the time of writing, the largest cohort of consecutive transplant recipients affected by COVID-19 with a relatively long median follow-up of approximately 2 months. It focuses only on symptomatic patients and analyzes the role of clinical features at admission and diagnosis on mortality risk. The quality of the data was guaranteed by maintaining constant communications with the contributing centers. Finally, the international multicentered pattern of the study copes with any individual center effect.

Some limitations are also to be acknowledged. Firstly, although we attempted to collect data on major covariables, there remains the possibility of missing confounders. Secondly, we focused on symptomatic patients with confirmed positive SARS-CoV-2 RT-PCR test despite test sensitivity <80%. Thus, some patients were excluded.

Conclusion

This study, including more than 240 LT recipients, confirmed that 25% of patients requiring hospitalization for COVID-19 died, the mortality risk being greater in patients aged older than 70 and with medical comorbidities such as impaired renal function and diabetes. Conversely, the use of TAC was associated with an increased survival probability. Although the biological explanation of this latter finding is currently unknown, our preliminary evidence should encourage clinicians to keep TAC at the usual dose because it may be beneficial when treating COVID-19. A more precise estimate of the protective effect of TAC requires studies on larger cohorts of transplant recipients.

Acknowledgments

ELITA board members Ulrich Baumann, Giacomo Germani, Silvio Nadalin, Pavel Taimr, Christian Toso, Roberto Trosi, and Krzysztof Zieniewicz supported and actively promoted the study. Maruska Nizzi provided linguistic and writing support. All centers participating in the ELITA/ELTR COVID-19 project in liver transplantation, including all collaborators at each site, are listed in Table 4 .

Table 4.

European Liver Transplantation Association/ European Liver Transplant Registry COVID-19 Registry for Liver Transplant Candidates and Recipients: Collaborators With Affiliations

1. Division of Transplantation, Department of Surgery, Medical University of Vienna, Austria: Gabriela Berlakovich, Dagmar Kollmann, Georg Györi
2. Universitair Ziekenhuis Antwerpen, Edegem, Belgium: Dirk Ysebaert, Patrick Hollants
3. Universitair Ziekenhuis Dienst voor Algemene en Hepatopancreaticobiliaire Heelkunde en Levertransplantatie, Ghent, Belgium: Frederik Berrevoet, Aude Vanlander
4. Universitair Ziekenhuis, Dienst Voor Levertransplantatie En Digestieve Heelkunde, Ghent, Belgium: Frederck Berrevoet, Eric Hoste, Christel Walraevens, Roberto Ivan Troisi
5. Liver Transplant Programme, University Leuven, Belgium: Jacques Pirenne, Frederick Nevens, Natalie Vandenende
6. CHU Liege,University of Liege, Belgium: Oliver Detry, Josee Monard, Nicolas Meurisse
7. Cliniques Universitaires Saint Luc, Catholic University of Louvain, Brussels, Belgium: Olga Ciccarelli
8. Hopital Erasme Universite Libre De Bruxelles, Department of Abdominal Surgery, Brussels, Belgium: Valerio Lucidi
9. Hopital Cantonal Universitaire De Geneve, Departement De Chirurgie, Geneva, Switzerland: Giulia Magini, Thierry Berney, Anne-Catherine Saouli
10. University Hospital Copenhagen, Department for Surgery and Transplantation Rigshospitalet, Copenhagen, Denmark: Allan Rasmussen
11. Hôpital De La Croix Rousse, Chirurgie Générale Et Digestive, Lyon, France: Sylvie Radenne, Mickael Lesurtel
12. Hôpital Henri Mondor, Service d’Hepatologie, Créteil, France: Christophe Duvoux, Norbert Ngongang
13. Hôpital Paul Brousse, Centre Hépato Biliaire, Villejuif, France: Audrey Coilly
14. C.H.R.U. De Strasbourg, Hôpital Hautepierre, Strasbourg, France: Francoise Faitot
15. Hepatogastroenterology Unit, Hopital Trousseau, C.H.R.U. de Tours, Tours, France: Laure Elkrief
16. Hôpital Bicêtre, Hépatologie et Transplantation Hépatique Pédiatriques, AP-HP Université Paris-Saclay, Le Kremlin-Bicêtre, France: Emmanuel Gonzales
17. The Queen Elizabeth Hospital, Queen Elisabeth Medical Center, Birmingham, United Kingdom: Darius Mirza, Thamara Perera, Hann Angus
18. University of Edinburgh Royal Infirmary, Liver Transplantation Unit, Edinburgh, United Kingdom: Gabriel Oniscu, Chris Johnston
19. Papa Giovanni XXIII Hospital, Chirurgia E Centro Trapianti Di Fegato, Bergamo, Italy: Luisa Pasulo, Michela Guizzetti, Marco Zambelli
20. Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy: Cristina Morelli, Giovanni Vitale
21. Istituto Nazionale Tumori Milano, Department of Hepatology, Hepato-pancreatic-biliary Surgery and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy: Sherrie Bhoori, Vincenzo Mazzaferro, Roberta Elisa Rossi
22. Ospedale Maggiore Di Milano, U.O. Chirurgia Generale E Dei Trapianti, Milano, Italy: Federica Invernizzi, Francesca Donato, Giorgio Rossi
23. Ospedale Niguarda Ca Granda, Hepatology and Gastroenterology Unit and Transplant Surgery Unit, Milano, Italy: Luca S Belli, Giovanni Perricone, Raffaella Viganò, Chiara Mazzarelli, Luciano De Carlis
24. University of Modena E Reggio Emilia, Policlinico Di Modena, Modena, Italy: Fabrizio Di Benedetto, Paolo Magistri, Antonia Zuliani
25. Ospedale Cisanello, U.O. Trapiantologia Epatica Universitaria Azienda Ospedaliera, Pisa, Italy: Paolo De Simone, Paola Carrai, Stefania Petruccelli
26. Liver Transplant Unit, AOU Città della Salute e della Scienza di Torino, Torino, Italy: Damiano Patrono, Silvia Martini, Renato Romagnoli
27. University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands: Aad Van Der Berg, Frank Cuperus
28. Erasmus MC, Transplant Insitute, University Medical Center Rotterdam, Department of Surgery, Divion of Hepatobiliry Surgery and Liver Transplantation, Rotterdam, The Netherlands: Wojciech Polak, Herold Metselaar
29. Hospital Gal De Santo Antonio, Department of Surgery and Organ Transplantation, Porto, Portugal: Jorge Daniel
30. Hospital General Universitario De Alicante, Unidad Transplantes Hepatico, Alicante, Spain: Gonzalo Rodriguez, Sonia Pascual
31. Hospital Clinic I Provincial De Barcelona, Gastrointestinal Surgery Department, Barcelona, Spain: Costantino Fondevila, Jorde Colmenero
32. Hospital Universitari De Bellvitge, Unidad De Trasplante Hepatico Unidad De Trasplante Hepatico, Barcelona, Spain: Laura LLado, Carme Baliellas
33. Hospital Universitari Vall D Hebron; Barcelona, Spain: Lluis Castells, Isabel Campos-Varela, Liver Unit; Ernest Hidalgo, Liver Transplant Unit
34. Hospital Universitario 12 de Octubre, HBP And Transplant Unit, General Surgery, Madrid, Spain: Carmelo Loinaz Segurola, Alberto Marcacuzco, Felix Cambra
35. Hospital Gregorio Maranon, Liver Transplant Unit, Madrid, Spain: Magdalena Salcedo Plaza, Fernando Diaz-Fontenla
36. Hospital Universitario Puerta de Hierro, Unidad de Trasplante Hepatico, Madrid, Spain: Valentin Cuervas-Mons, Ana Arias Milla, Alejandro Muñoz
37. Liver Transplant Unit, Hospital Virgen del Rocio, Seville, Spain: Jose Maria Alamo
38. Cirurgia HPB y Transplante Hepatico, Hospital Universitario de Badajoz, Spain: Gerardo Blanco
39. Hospital Universitario, Virgen De La Arrixaca, El Palmar (Murcia), Spain: Victor Lopez Lopez.
40. Clinica Universitaria, Universidad De Navarra, Facultad De Medicina, Pamplona, Spain: Pablo Marti-Cruchaga
41. Hospital Universitario Marques De Valdecilla, Unidad De Traspante Hepatico, Santander, Spain: Rodriguez San Juan
42. Hospital Universitario Virgen De La Nieves, Servicio De Cirugia General, Granada, Spain: Esther Brea Gomes
43. Huddinge Hospital, Department of Transplantation Surgery, Huddinge, Sweden: Bo Goran Ericzon, Carl Jorns

CRediT Authorship Contributions

Luca Saverio Belli, MD (Conceptualization: Lead; Investigation: Equal; Project administration: Lead; Writing – original draft: Lead). Constantino Fondevila, Dr (Supervision: Equal; Writing – review & editing: Supporting). Sara Conti, Dr (Formal analysis: Lead; Methodology: Equal). Paolo Cortesi, Dr (Formal analysis: Lead; Methodology: Lead). Vincent Karam, PhD (Writing – review & editing: Supporting). Rene Adam, MD (Conceptualization: Equal; Supervision: Equal; Writing – review & editing: Equal). Audrey Coilly, Professor (Investigation: Equal). Bo-Goran Ericzon, Dr (Investigation: Equal). Carmelo Loinaz, Dr (Investigation: Equal). Valentin Cuervas-Mons, Dr (Investigation: Equal). Marco Zambelli, Dr (Investigation: Equal). Laura Llado, Dr (Investigation: Equal). Fernando Diaz, Dr (Investigation: Equal). Federica Invernizzi, Dr (Investigation: Equal). Damiano Patrono, Dr (Investigation: Equal). Francois Faitot, Dr (Investigation: Equal). Sherrie Boohrie, MD (Investigation: Equal). Jaques Pirenne, Professor (Investigation: Equal). Giovanni Perricone, MD (Investigation: Equal; Writing – review & editing: Equal). Giulia Magini, MD (Investigation: Equal). Lluis Castells, MD (Data curation: Equal; Validation: Supporting). Oliver Detry, MD (Investigation: Equal). Pablo Marti-Cruchaga, MD (Investigation: Equal). Jordi Colmenero, MD (Investigation: Equal). Frederick Berrevoet, MD (Investigation: Equal). Gonzalo Rodriguez, MD (Investigation: Equal). Dirk Ysebaert, MD (Investigation: Equal). Sylvie Radenne, MD (Investigation: Equal). Herold Metselaar, Professor (Investigation: Equal). Maria Cristina Morelli, MD (Investigation: Equal). De Carlis Luciano, MD (Writing – review & editing: Supporting). Wojciech Polak, MD (Conceptualization: Equal; Investigation: Equal; Writing – review & editing: Equal). Christophe Duvoux, Professor (Conceptualization: Equal; Methodology: Equal; Writing – review & editing: Equal).

Footnotes

Conflicts of interest The authors disclose no conflicts.

Funding No funding was received.

Author names in bold designate shared co-first authorship.

Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at https://doi.org/10.1053/j.gastro.2020.11.045.

Supplementary Materials

Supplementary Table 1.

Results From Multivariate Analysis of Predictors of Mortality, From Cox’s Proportional Hazard Regression Models, Excluding Age From the Predictors

Variable HR (95% CI) P value
Comorbidities
 Diabetes 1.95 (1.06–3.58) .0313
 Chronic kidney diseasea 1.97 (1.05–3.67) .0336
 Other 1.92 (0.97–3.82) .0608
 Main immunosuppressant (TAC vs CsA/mTOR/MMF) 0.52 (0.29–0.95) .0325

NOTE. Predictors with a P value ≤.1 were retained in the model. Bold values are statistically significant (P < .05).

HR, hazard ratio; mTOR, mammalian target of rapamycin inhibitor.

a

Plasma creatinine >2 mg/dL.

Supplementary Table 2.

Estimated Probability of Survival 50 Days After the Symptoms, Stratified by Age (2 Categories), Main Immunosuppressant and Chronic Kidney Disease

Age Main Immunosuppressant Chronic kidney diseasea Patients (n) Probability of survival at 50 days (95% CI)
≤ 70 y TAC No 113 0.89 (0.82–0.94)
Yes 16 0.86 (0.55–0.96)
CsA/mTOR/MMF/other No 39 0.90 (0.75–0.96)
Yes 13 0.54 (0.25–0.76)
>70 y TAC No 16 0.75 (0.46–0.90)
Yes 10 0.77 (0.34–0.94)
CsA/mTOR/MMF/other No 20 0.50 (0.27–0.69)
Yes 7 0.29 (0.01–0.69)

NOTE. Estimates are based on Kaplan-Meier curves.

mTOR, mammalian target of rapamycin inhibitor

a

Plasma creatinine >2 mg/dL.

Supplementary Table 3.

Baseline Characteristics of the Study Population, Stratified by Type of Calcineurin Inhibitor

Variables Immunosuppressant
Total (N = 243) P value
CsA/other (n = 81) TAC (n = 162)
Male sex 66 (81.48) 105 (64.81) 171 (70.37) .0073
Age at symptoms, y 68 (60.5–73.5) 61 (53.0–68.0) 63 (55.0–69.0)
Location of patient at occurrence of symptoms .4631
 Home 74 (91.36) 143 (88.27) 217 (89.30)
 Hospital 7 (8.64) 19 (11.73) 26 (10.70)
Place of management .0831
 Home 7 (8.64) 32 (19.75) 39 (16.05)
 Ward 61 (75.31) 106 (65.43) 167 (68.72)
 ICU 13 (16.05) 24 (14.81) 37 (15.23)
Time between last LT and COVID-19 symptoms, y 12 (6.2–18.9) 7 (2.0–13.3) 8 (3.1–15.0)
 Missing 1 (1.23) 5 (3.09) 6 (2.47)
Indication for LT
 Decompensated cirrhosis 51 (62.96) 90 (55.56) 141 (58.02) .27
 Hepatocellular carcinoma 21 (25.93) 42 (25.93) 63 (25.93) >.9999
 Other 9 (11.11) 31 (19.14) 40 (16.46) .1118
Body mass index, kg/m2 26.3 (23.5–29.7) 25.7 (23.4–29.4) 25.9 (23.4–29.4) .6612
Chronic kidney diseasea 22 (27.16) 27 (16.67) 49 (20.16) .0546
Coronary artery disease 3 (3.70) 14 (8.64) 17 (7.00) .1548
Comorbidities, n .0003
 0 11 (13.58) 46 (28.40) 57 (23.46)
 1 20 (24.69) 59 (36.42) 79 (32.51)
 ≥2 50 (61.73) 57 (35.19) 107 (44.03)
Drugs
 β-Blockers 20 (24.69) 30 (18.52) 50 (20.58) .2618
 ACE inhibitors or angiotensin II receptor antagonists 33 (40.74) 26 (16.05) 59 (24.28) <.0001
Type of immunosuppressant
 CsA 29 (35.80) 0 (0.00) 29 (11.93) <.0001
 TAC 0 (0.00) 162 (100.00) 162 (66.67) <.0001
 MMF 50 (61.73) 69 (42.59) 119 (48.97) .0049
 mTOR inhibitor 23 (28.40) 14 (8.64) 37 (15.23) <.0001
 Steroids 14 (17.28) 42 (25.93) 56 (23.05) .1316
 Other 0 (0.00) 1 (0.62) 1 (0.41) >.9999
Outcome .0033
 Alive 56 (69.14) 138 (85.19) 194 (79.84)
 Dead 25 (30.86) 24 (14.81) 49 (20.16)
Time between symptoms and last follow-up, d 60 (23–83) 66 (39–87) 65 (35–87) .127
 Missing 1 (1.23) 5 (3.09) 6 (2.47)
Cause of death
 Refractory pneumonia 21 (84.00) 17 (70.83) 38 (77.55) .2695
 Liver-related death
 Without lung failure 0 (0.00) 1 (4.17) 1 (2.04) .4898
 With lung failure 2 (8.00) 1 (4.17) 3 (6.12) >.9999
 Other 2 (8.00) 5 (20.83) 7 (14.29) .2467

NOTE. Data are presented n (%) or median (1st–3rd quartile).

mTOR, mammalian target of rapamycin.

a

Plasma creatinine >2 mg/dL.

References

  • 1.ZhouF YuT., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet 2020;395:1038] Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.European Liver Transplant Registry (ELTR) www.eltr.eu Accessed July 2020.
  • 3.Bhoori S., Rossi R.E., Citterio D. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5:532–533. doi: 10.1016/S2468-1253(20)30116-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fernández-Ruiz M., Andrés A., Loinaz C. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020;20:1849–1858. doi: 10.1111/ajt.15929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Pereira M.R., Mohan S., Cohen D.J. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808. doi: 10.1111/ajt.15941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Webb G.J., Moon A.M., Barnes E. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol. 2020;5:643–644. doi: 10.1016/S2468-1253(20)30125-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Belli L.S., Duvoux C., Karam V. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol. 2020;5:724–725. doi: 10.1016/S2468-1253(20)30183-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Polak W.G., Fondevila C., Karam V. Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. Transpl Int. 2020;33:1244–1252. doi: 10.1111/tri.13680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Becchetti C., Zambelli M.F., Pasulo L. COVID-19 in an international European liver transplant recipient cohort. Gut. 2020;69:1832–1840. doi: 10.1136/gutjnl-2020-321923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Carbajo-Lozoya J., Müller M.A., Kallies S., Thiel V., Drosten C., von Brunn A. Replication of human coronaviruses SARS-CoV, HCoVNL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165:112–117. doi: 10.1016/j.virusres.2012.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.World Health Organization Coronavirus disease (COVID-19) pandemic. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed July 2020.
  • 12.Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Richardson S., Hirsch J.S., Narasimhan M. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–2059. doi: 10.1001/jama.2020.6775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wu C., Chen X., Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943. doi: 10.1001/jamainternmed.2020.0994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Russell B., Moss C., George G. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. doi: 10.3332/ecancer.2020.1022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tanaka Y., Sato Y., Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 2013;5:1250–1260. doi: 10.3390/v5051250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Willicombe M., Thomas D., McAdoo S. COVID-19 and calcineurin inhibitors: should they get left out in the storm? J Am Soc Nephrol. 2020;31:1145–1146. doi: 10.1681/ASN.2020030348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Guan W.J., Liang W.H., Zhao Y. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55 doi: 10.1183/13993003.00547-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Tovikkai C., Charman S.C., Praseedom Time varying impact of comorbidities on mortality after liver transplantation: a national cohort study using linked clinical and administrative data. BMJ Open. 2015;5 doi: 10.1136/bmjopen-2014-006971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Horby P., Lim W.S., Emberson J.R. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. https://doi.org/10.1056/N Engl J Moa2021436 Published online July 17, 2020.
  • 21.Beigel J.H., Tomashek K.M., Dodd L.E. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2007764 Published online May 22, 2020. [DOI] [PubMed]

Articles from Gastroenterology are provided here courtesy of Elsevier

RESOURCES